Jianming Bao

This inventor holds 43 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 12 EPO patents, primarily in Pharmaceutical Inhibitors. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Msd R&d (China) Co., Ltd.. Active years: 1997-2026.

USPTO Granted Patents = 43 (Patent Applications = 8)

% Patents Active = 93.0

CIPO Patents = 2 (Patent Applications = 10)

EPO Patents = 12 (Patent Applications = 18)

Average Co-Inventor Count = 7.1

ph-index = 10

Forward Citations = 228(Granted Patents)

Location History:

Westfield, NJ (US) (1997 - 1999)
Scotch Plains, NJ (US) (1999 - 2011)
Shanghai, CN (2017 - 2019)
San Mateo, CA (US) (2021 - 2022)
Princeton, NJ (US) (2012 - 2024)
South San Francisco, CA (US) (2021 - 2024)

Company Filing History:

21 out of 2,405

Merck Sharp + Dohme Corp.

Msd R&d (China) Co., Ltd.

patents

4. 3 out of 63

Merck Sharp & Dohme LLC

patents

5. 3 out of 64

Metabasis Therapeutics, Inc.

patents

6. 1 out of 1

Merck Msd (r&d) China Co., Ltd.

patent

where one patent can have more than one assignee

Years Active: 1997-2026

Loading Chart...

Areas of Expertise:

Diacylglyceride Inhibitors

M4 Muscarinic Receptor

TrkA Kinase Inhibitors

Cyclic Benzimidazole

Potassium Channel Inhibitors

Immunosuppressant Compounds

Allosteric Modulators

Spirocyclic CETP Inhibitors

Triterpene Derivatives

Anti-Diabetic Agents

Heterocyclic Compounds

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679848 - Plasma kallikrein inhibitors (2026-07-14),

2. 12540132 - Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors (2026-02-03),

3. 12528786 - Plasma kallikrein inhibitors (2026-01-20),

4. 12459927 - Plasma kallikrein inhibitors (2025-11-04),

5. 12448384 - Diacylglyceride O-acyltransferase 2 inhibitors (2025-10-21),

6. 12428411 - Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors (2025-09-30),

7. 12410159 - Preparation of oxindole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors (2025-09-09),

8. 11976061 - Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors (2024-05-07),

9. 11970479 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor (2024-04-30),

10. 11339156 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor (2022-05-24),

11. 11319298 - Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor (2022-05-03),

12. 11149036 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor (2021-10-19),

13. 10981902 - 5-(pyridin-3-yl)oxazole allosteric modulators of the M4 muscarinic acetylcholine receptor (2021-04-20),

14. 10933056 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor (2021-03-02),

15. 10329289 - 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor (2019-06-25),

Title: Inventor Jianming Bao

Introduction: Jianming Bao is a prolific inventor based in San Mateo, California, known for his groundbreaking contributions to various technological fields.

Latest Patents: Jianming Bao holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise.

Career Highlights: With a career spanning over two decades, Jianming Bao has worked with leading tech companies and research institutions, consistently pushing the boundaries of innovation.

Collaborations: Throughout his career, Jianming Bao has collaborated with top scientists, engineers, and researchers globally, fostering a culture of innovation and knowledge sharing.

Conclusion: Jianming Bao's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and researchers worldwide.